Trials / Completed
CompletedNCT00491491
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ibritumomab tiuxetan | 0.4 mCi/kg |
| PROCEDURE | BEAM chemotherapy and autologous stem-cell transplantation |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2007-06-26
- Last updated
- 2020-08-31
- Results posted
- 2020-08-31
Locations
9 sites across 4 countries: United States, Germany, Israel, Netherlands
Source: ClinicalTrials.gov record NCT00491491. Inclusion in this directory is not an endorsement.